PubRank

José Alexandre S Crippa

Author PubWeight™ 47.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2010 1.55
2 Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011 1.41
3 Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol 2007 1.40
4 [Factorial structure of the Brazilian version of the Modified Reasons for Smoking Scale]. Rev Assoc Med Bras 2009 1.08
5 Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006 1.08
6 Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011 1.03
7 Altered gray matter morphometry and resting-state functional and structural connectivity in social anxiety disorder. Brain Res 2011 1.03
8 Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2011 1.03
9 The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 2009 1.02
10 Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. Schizophr Res 2010 0.94
11 Structural magnetic resonance imaging in anxiety disorders: an update of research findings. Rev Bras Psiquiatr 2008 0.92
12 National Science and Technology Institute for Translational Medicine (INCT-TM): advancing the field of translational medicine and mental health. Rev Bras Psiquiatr 2010 0.91
13 Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) 2011 0.90
14 Psychometric qualities of the Brazilian versions of the Fagerström Test for Nicotine Dependence and the Heaviness of Smoking Index. Nicotine Tob Res 2009 0.90
15 Neuroimaging in specific phobia disorder: a systematic review of the literature. Rev Bras Psiquiatr 2012 0.89
16 Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr 2012 0.89
17 Social anxiety disorder women easily recognize fearfull, sad and happy faces: the influence of gender. J Psychiatr Res 2009 0.89
18 Evaluation of the psychometric properties of the Social Phobia Inventory in university students. Compr Psychiatry 2010 0.88
19 Social phobia in Brazilian university students: prevalence, under-recognition and academic impairment in women. J Affect Disord 2011 0.86
20 Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. J Clin Psychopharmacol 2016 0.86
21 The accuracy of diagnosis of major depression in patients with Parkinson's disease: a comparative study among the UPDRS, the geriatric depression scale and the Beck depression inventory. Arq Neuropsiquiatr 2008 0.85
22 Oxytocin interference in the effects induced by inhalation of 7.5% CO(2) in healthy volunteers. Hum Psychopharmacol 2012 0.84
23 Further study of the psychometric qualities of a brief screening tool for social phobia (MINI-SPIN) applied to clinical and nonclinical samples. Perspect Psychiatr Care 2010 0.83
24 [Guidelines of the Brazilian Medical Association for the diagnosis and differential diagnosis of social anxiety disorder]. Rev Bras Psiquiatr 2010 0.83
25 Are there differences between early- and late-onset social anxiety disorder? Rev Bras Psiquiatr 2007 0.82
26 Further psychometric study of the Beck Anxiety Inventory including factorial analysis and social anxiety disorder screening. Int J Psychiatry Clin Pract 2011 0.82
27 Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder. J Clin Psychiatry 2005 0.82
28 Cross- cultural validation of the Brazilian Portuguese version of the Social Phobia Inventory (SPIN): study of the items and internal consistency. Rev Bras Psiquiatr 2008 0.82
29 The fast alcohol screening test (FAST) is as good as the AUDIT to screen alcohol use disorders. Subst Use Misuse 2010 0.81
30 Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr 2010 0.80
31 Anxiety and joint hypermobility association: a systematic review. Rev Bras Psiquiatr 2012 0.80
32 Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins. Mol Neurobiol 2014 0.79
33 Psychometrics properties of early trauma inventory self report - short form (ETISR-SR) for the Brazilian context. PLoS One 2013 0.79
34 Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology 2011 0.79
35 Agomelatine in the treatment of social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010 0.79
36 A motivational profile for smoking among adolescents. J Addict Med 2013 0.78
37 Why should Cannabis be Considered Doping in Sports? Front Psychiatry 2013 0.78
38 [Cannabis sativa: the plant that can induce unwanted effects and also treat them]. Rev Bras Psiquiatr 2010 0.78
39 Disability profile/clinician-rated: validity for Brazilian university students with social anxiety disorder. Span J Psychol 2013 0.78
40 NMDA and AMPA/kainate glutamatergic receptors in the prelimbic medial prefrontal cortex modulate the elaborated defensive behavior and innate fear-induced antinociception elicited by GABAA receptor blockade in the medial hypothalamus. Cereb Cortex 2013 0.77
41 Duloxetine in the treatment of panic disorder. Int J Neuropsychopharmacol 2005 0.77
42 Adaptation and initial psychometric study of the self-report version of Liebowitz Social Anxiety Scale (LSAS-SR). Int J Psychiatry Clin Pract 2012 0.77
43 Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol 2013 0.77
44 Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson's disease. Parkinsonism Relat Disord 2009 0.77
45 Social anxiety and negative early life events in university students. Rev Bras Psiquiatr 2012 0.77
46 Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res 2013 0.77
47 Is the Fagerström Test for Nicotine Dependence a good instrument to assess tobacco use in patients with schizophrenia? Rev Bras Psiquiatr 2009 0.77
48 Validation and internal consistency of Patient Health Questionnaire-9 for major depression in Parkinson's disease. Age Ageing 2013 0.76
49 Higher prevalence of major depressive symptoms in Brazilians aged 14 and older. Rev Bras Psiquiatr 2013 0.76
50 Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. Mol Neurobiol 2013 0.76
51 Neuroimaging of depression in Parkinson's disease: a review. Int Psychogeriatr 2013 0.76
52 Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning? Expert Rev Neurother 2011 0.76
53 Does social phobia remain the 'Ugly Duckling' of anxiety disorders? Rev Bras Psiquiatr 2009 0.76
54 Effects of pregabalin on behavioral alterations induced by ketamine in rats. Rev Bras Psiquiatr 2012 0.75
55 Depressive symptoms and alcohol correlates among Brazilians aged 14 years and older: a cross-sectional study. Subst Abuse Treat Prev Policy 2014 0.75
56 Trismus induced by fluoxetine. J Clin Psychopharmacol 2009 0.75
57 Assessment of referrals to an OT consultation-liaison service: a retrospective and comparative study. Scand J Occup Ther 2010 0.75
58 Brazil launches an innovative program to develop the National Institutes for Science and Technology (INCTs): the INCT for Translational Medicine. Rev Bras Psiquiatr 2009 0.75
59 Validation of the state version of the Self-Statement during Public Speaking Scale. Rev Bras Psiquiatr 2013 0.75
60 On museums and scientific journals. Rev Bras Psiquiatr 2012 0.75
61 Pharmacotherapy treatment of depression in patients with neurodegenerative diseases: where are we? Arq Neuropsiquiatr 2012 0.75
62 New trends in anxiety disorders. Rev Bras Psiquiatr 2012 0.75